MTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors

Breast

Volumn 21, Issue 2, 2012, Pages 178-182

  Walsh, S ^a   Flanagan, L ^b   Quinn, C ^b   Evoy, D ^a   McDermott, E W ^a   Pierce, A ^a   Duffy, M J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Breast cancer; MTOR; Rapamycin; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOGENESIS; CANCER GRADING; CANCER INVASION; CANCER MORPHOLOGY; CANCER SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84858749047     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.09.008     Document Type: Article

References (16)

1. Podo F, Buydens LMC, Degani H, Buydens LM, Degani H, Hilhorst R, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 4(3): p. 209-229.
2. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20(12):1913-1927.
3. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430.
4. Laplante M., Sabatini D.M. mTOR signaling at a glance. J Cell Sci 2009, 122(Pt 20):3589-3594.
5. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 28(6): pp. 1075-1083.
6. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 28(20): pp. 3366-3379.
7. Mabuchi S., Kawase C., Altomare D.A., Morishige K., Sawada K., Hayashi M., et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009, 15(17):5404-5413.
8. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13(19):5883-5888.
9. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70(1): p. 288-298.
10. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41(3A):154-161.
11. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol, in press.
12. Bose S., Chandran S., Mirocha J.M., Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19(2):238-245.
13. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10(20):6779-6788.
14. Yaba A., Bianchi V., Borini A., Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod Sci 2008, 15(2):128-138.
15. Vazquez-Martin A., Oliveras-Ferraros C., Bernadó L., López-Bonet E., Menendez J.A. The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. Biochem Biophys Res Commun 2009, 380(3):638-643.
16. Tsang CK, Liu H, Zheng XF. mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. Cell Cycle. 9(5): pp. 953-957.